1. Medtech Insight

One Cell Systems (US) to combine gel microdrop (GMD) with fluorescence activated cell sorting (FACS)

One Cell Systems (US) has received a $100,000 grant from the US NIH to evaluate the combined use of its gel microdrop technology and fluorescence activated cell sorting (FACS) to develop a rapid method for screening micro-organisms. The encapsulating technology, licensed to One Cell by the Harvard-Massachusetts Institute of Technology, is said to be well suited to automation as it is compatible with a broad spectrum of existing sample preparation and analytical technologies.

One Cell Systems (US) has received a $100,000 grant from the US NIH to evaluate the combined use of its gel microdrop technology and fluorescence activated cell sorting (FACS) to develop a rapid method for screening micro-organisms. The encapsulating technology, licensed to One Cell by the Harvard-Massachusetts Institute of Technology, is said to be well suited to automation as it is compatible with a broad spectrum of existing sample preparation and analytical technologies.

Founded in 1991, Cambridge, Massachusetts-based One Cell Systems has been financed by venture capital, research grants and development agreements with biopharmaceutical companies. Among projects funded by the NIH are assay...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.